Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 801–900 of 1,038
Lipoprotein metabolism in nonalcoholic fatty liver disease
Jiang, Z. G., Simon, K. A., & Zemin, Y. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20120077 · Cited by 103
Resolution of inflammation in obesity-induced liver disease
Rius, B., López-Vicario, C., González-Périz, A., Morán-Salvador, E., García-Alonso, V., Clária, J., & Titos, E. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00257 · Cited by 79
“This connection is exemplified by the observation that the circulating fatty acid pool derived from fat is the primary contributor to hepatic steatosis, the initial stage in non-alcoholic steatohepatitis (Donnelly et al., 2005).”
BackgroundHepatitis C and diabetes: the inevitable coincidence?
Lonardo, A., Adinolfi, L. E., Petta, S., Craxì, A., & Loria, P. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.3 · Cited by 93
Donné, R., Saroul-Aïnama, M., Cordier, P., Hammoutène, A., Kaboré, C., Stadler, M., Nemazanyy, I., Galy–Fauroux, I., Herrag, M., Riedl, T., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.06.003 · Cited by 90
Fructose drives de novo lipogenesis affecting metabolic health
Geidl, B., & Gerber, P. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0270 · Cited by 103
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 92
“The increased lipolysis of TGs in the adipose tissue increases plasma levels of non-esterified fatty acids (NEFA) and glycerol [11,30–34].”
BackgroundInfluentialGrandone, A., Cozzolino, D., Marzuillo, P., Cirillo, G., Sessa, A. D., Ruggiero, L., Palma, M. R. D., Perrone, L., & del Giudice, E. M. (2015) · Pediatric Obesity · doi:10.1111/ijpo.12032 · Cited by 86
“NAFLD may occur in overweight and obese children representing the result of an intrahepatic accumulation of TGs (20,21).”
BackgroundInfluentialMacías, J., González, J., Tural, C., González, E. O., Pulido, F., Rubio, R., Cifuentes, C., Díaz‐Menéndez, M., Jou, A., Rubio, P., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000248 · Cited by 88
“In obese patients with hepatic steatosis, an increased delivery of free fatty acids to the liver and de-novo lipogenesis is observed [28].”
BackgroundCarotenoids and non-alcoholic fatty liver disease.
Yılmaz, B., Şahin, K., Bilen, H., Bahçecioğlu, İ. H., Bilir, B., Ashraf, S., Halazun, K. J., & Küçük, Ö. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.01.11 · Cited by 99
“FFAs are responsible for approximately two-thirds of accumulated lipid in liver (22).”
BackgroundNon-alcoholic Fatty Liver Disease in Children
Manco, M., Bottazzo, G. F., Vito, R. D., Marcellini, M., Mingrone, G., & Nobili, V. (2008) · touchREVIEWS in Endocrinology · doi:10.1080/07315724.2008.10719744 · Cited by 87
“A decreased hepatic rate of lipid export, due to reduced apo-lipoprotein B synthesis and/or excretion and consequently, defective incorporation of triglycerides into the lipoproteins, may further exacerbate fat storage in liver [23].”
BackgroundInfluentialNonalcoholic fatty liver disease: a challenge for pediatricians
Widhalm, K., & Ghods, E. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.185 · Cited by 91
Jump, D. Β., Depner, C. M., Tripathy, S., & Lytle, K. A. (2015) · Advances in Nutrition · doi:10.3945/an.115.009423 · Cited by 93
“In humans with NAFLD, ;60% of the FAs appearing in the liver are derived from circulating nonesterified FAs mobilized from adipose tissue; 26% are from DNL and 15% from diet (40).”
BackgroundMammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases
Kaur, A., & Sharma, S. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0336-1 · Cited by 93
“deposition of triglycerides in the liver of obese humans is related to the stimulation of lipogenesis in hepatocytes (Donnelly et al. 2005).”
Parks, E. J., & Hellerstein, M. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600018-jlr200 · Cited by 85
“Furthermore, in these subjects, fractional lipogenesis failed to increase significantly with meal consumption (51), suggesting that DNL is contributing significantly to hepatic-TG stores and that the process may have reached a maximum value in insulin-resistant subjects.”
Self-citationTruong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“For additional information, please refer to the literature [60,67].”
InfluentialCirculating microRNAs in patients with non-alcoholic fatty liver disease
Celikbilek, M., Baskol, M., Taheri, S., Deniz, K., Dogan, S., Zararsiz, G., Gursoy, S., Guven, K., Ozbakır, O., Dundar, M., et al. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i8.613 · Cited by 84
Yuan, F., Wang, H., Tian, Y. T., Li, Q., He, L., Li, N., & Liu, Z. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0190-y · Cited by 88
“Besides the de novo lipogenesis, the expression of genes involved in liver lipid uptake from the circulation (CD36 and slc27a2) [17], fatty acids beta-oxidation in the mitochondria (Cpt1a, Cpt2, Acadl, and Acaa1b) and TG export (Apob and Mttp) [25, 26] were regulated by fish oil feeding.”
BackgroundRan, S., Zhang, J., Tian, F., Qian, Z. M., Wei, S., Wang, Y., Chen, G., Zhang, J., Arnold, L. D., McMillin, S. E., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.033 · Cited by 92
van Greevenbroek, M. M. J., Jacobs, M., van der Kallen, C. J. H., Vermeulen, V. M. M.-J., Jansen, E. H. J. M., Schalkwijk, C. G., Ferreira, I., Feskens, E. J. M., & Stehouwer, C. D. A. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02418.x · Cited by 85
Pathil, A., Mueller, J., Warth, A., Chamulitrat, W., & Stremmel, W. (2011) · Hepatology · doi:10.1002/hep.25531 · Cited by 87
“Although de novo lipogenesis contributes only approximately 5% to the fatty acid pool of the liver under healthy conditions, it may account for up to 26% of total fatty acids in NASH.41 We were able to establish that treatment with UDCA-LPE achieved a clear reduction in genes participating in the fatty acid burden of…”
BackgroundInfluentialMetabolic correlates of nonalcoholic fatty liver in women and men
Vega, G. L., Chandalia, M., Szczepaniak, L. S., & Grundy, S. M. (2007) · Hepatology · doi:10.1002/hep.21727 · Cited by 84
Hu, M., Chu, W. C. W., Yamashita, S., Yeung, D. K. W., Shi, L., Wang, D., Masuda, D., Yang, Y., & Tomlinson, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023614 · Cited by 81
Catalase and nonalcoholic fatty liver disease
Shin, S., Cho, H.-W., Song, S.-E., & Song, D. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2195-z · Cited by 89
Williams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
“Plasma nonesterified fatty acids from adipose lipolysis (and some spillover from lipoprotein hydrolysis) contibute 59%, while diet supplies the remaining 15% via hepatic uptake of intestinally derived C-TRL remnants [419].”
BackgroundInfluentialJeong, H.-S., Cho, Y.-H., Kim, K., Kim, Y., Kim, K., Na, Y., Park, J., Lee, I., Lee, J. H., & Jang, H.-J. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1181-2 · Cited by 83
“This result suggests that the effect of AOE on lipid accumulation is associated with the DNL process.”
BackgroundInfluentialEvaluating causality of cellular senescence in non-alcoholic fatty liver disease
Meijnikman, A. S., Herrema, H., Scheithauer, T. P. M., Kroon, J., Nieuwdorp, M., & Groen, A. K. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100301 · Cited by 75
“example, insulin resistance increases circulating free fatty acid (FFA) levels by reducing insulinmediated suppression of lipolysis in the visceral adipose tissue compartment.(15) This increases the hepatocellular influx of FFAs which may subsequently be stored as triglycerides.”
BackgroundSex hormone–binding globulin: biomarker and hepatokine?
Simons, P. I. H. G., Valkenburg, O., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.05.002 · Cited by 90
Kurtz, C. L., Fannin, E. E., Toth, C. L., Pearson, D. S., Vickers, K. C., & Sethupathy, P. (2015) · Scientific Reports · doi:10.1038/srep12911 · Cited by 91
Inflammation in nonalcoholic steatohepatitis
Harmon, R. C., Tiniakos, D. G., & Argo, C. K. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.21 · Cited by 84
Nobili, V., Alisi, A., & Raponi, M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.6017 · Cited by 80
Girard, J. R., & Lafontan, M. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.04.002 · Cited by 95
Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes
Cook, J. R., Langlet, F., Kido, Y., & Accili, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.638197 · Cited by 83
Regulation of hepatic gene expression by saturated fatty acids
Vallim, T., & Salter, A. M. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.02.016 · Cited by 96
Linden, M. A., Fletcher, J. A., Morris, E. M., Meers, G. M., Kearney, M. L., Crissey, J. M., Laughlin, M. H., Booth, F. W., Sowers, J. R., Ibdah, J. A., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00427.2013 · Cited by 81
“Additionally, recent work has indicated that 25% of hepatic TG accumulation can be accounted for by de novo lipogenesis in NAFLD patients (9).”
BackgroundRole of folate in nonalcoholic fatty liver disease
Sid, V., Siow, Y. L., & Karmin, O. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0681 · Cited by 88
“Such an increase in lipid biosynthesis may contribute to hepatic lipid accumulation (Donnelly et al. 2005).”
BackgroundIsorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
Ganbold, M., Owada, Y., Ozawa, Y., Shimamoto, Y., Ferdousi, F., Tominaga, K., Zheng, Y., Ohkohchi, N., & Isoda, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-52736-y · Cited by 84
George, J., & Liddle, C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 81
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
Liu, Y., Xie, C., Zhai, Z., Deng, Z., de Jonge, H. R., Wu, X., & Ruan, Z. (2021) · Food & Function · doi:10.1039/d0fo02533j · Cited by 87
Flessa, C., Kyrou, I., Ansari, N. N., Kaltsas, G., Papavassiliou, A. G., Kassi, E. N., & Randeva, H. S. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00431-3 · Cited by 86
Pediatric fatty liver disease: Role of ethnicity and genetics
Marzuillo, P., del Giudice, E. M., & Santoro, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7347 · Cited by 87
Davis, J., Higginbotham, A., O’Connor, T., Moustaid-Moussa, N., Tebbe, A., Kim, Y.-C., Cho, K. W., Shay, N., Adler, S., Peterson, R., et al. (2007) · Annals of Nutrition and Metabolism · doi:10.1159/000100820 · Cited by 82
“Moreover, aberrant peripheral FA metabolism has been suggested to contribute to accumulation of lipid in liver, as well as plasma lipoprotein [”
BackgroundThe role of angiotensin II in nonalcoholic steatohepatitis
Morris, E. M., Fletcher, J. A., Thyfault, J. P., & Rector, R. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.04.013 · Cited by 89
Utzschneider, K. M., Bayer-Carter, J. L., Arbuckle, M. D., Tidwell, J. M., Richards, T. L., & Craft, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512002966 · Cited by 81
“30 % energy from fat, 15 % of the TAG in the liver was derived directly from dietary fat((3)).”
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144079 · Cited by 81
“…accumulation by increasing the inflow or synthesis of lipids in the liver (i.e., by stimulating hepatic lipid uptake or hepatic de novo lipogenesis [DNL]), or by blocking lipid catabolism or outflow (i.e., by reducing hepatic β -oxidation or very low-density lipoprotein [VLDL] secretion) (10–16).”
To die or not to die: death signaling in nonalcoholic fatty liver disease
Akazawa, Y., & Nakao, K. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1451-5 · Cited by 86
“However, obesity and insulin resistance trigger adipocytes to release increased levels of circulating FFAs into the bloodstream, which then enter hepatocytes [15].”
BackgroundMännistö, V., Simonen, M., Hyysalo, J., Soininen, P., Kangas, A. J., Kamińska, D., Matte, A. K., Venesmaa, S., Käkelä, P., Kärjä, V. J., et al. (2014) · Liver International · doi:10.1111/liv.12769 · Cited by 88
“However, it has remained unclear whether fatty acid oxidation is increased (9, 13, 14) in human NAFLD/NASH or not (12, 15).”
BackgroundInfluentialTan, H., Zain, S. M., Mohamed, R. B., Rampal, S., Chin, K. F., Basu, R. C., Cheah, P., Mahadeva, S., & Mohamed, Z. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0850-x · Cited by 83
“Malonyl coenzyme A (CoA), a substrate for de novo lipogenesis, increases fat deposition in the liver and blocks fatty acid oxidation [29, 31].”
BackgroundDel Bo’, C., Perna, S., Allehdan, S., Rafique, A., Saad, S., AlGhareeb, F., Rondanelli, M., Tayyem, R. F., Marino, M., Martini, D., et al. (2023) · Nutrients · doi:10.3390/nu15102250 · Cited by 80
“SFA may promote cellular dysfunction by activating ER stress pathways, upregulating NAFLD-associated pathways, and both systemic and hepatic insulin resistance, as well as contributing to the intrahepatic triglyceride (IHTG) pool [69,70].”
BackgroundLi, M., Reynolds, C. M., Segovia, S. A., Gray, C. L., & Vickers, M. H. (2015) · BioMed Research International · doi:10.1155/2015/437107 · Cited by 91
“demonstrated, using stable isotopes, that the dominant source of fat which accumulated in liver originates from serum free fatty acids; this is closely followed by de novo lipogenesis [52].”
BackgroundChung, J., Koo, K., Lian, F., Hu, K. Q., Ernst, H., & Wang, X. (2012) · Journal of Nutrition · doi:10.3945/jn.111.150052 · Cited by 86
Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP
Papazyan, R., Sun, Z., Kim, Y. H., Titchenell, P. M., Hill, D. A., Lu, W., Damle, M., Wan, M., Zhang, Y., Briggs, E. R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.012 · Cited by 76
“Furthermore, in addition to lipogenesis, abnormal fatty acid uptake, oxidation, and secretion can also contribute to fatty liver formation (Donnelly et al., 2005; Lambert et al., 2014; Sunny et al., 2011).”
BackgroundSmith, B. K., Ford, R. J., Desjardins, E. M., Green, A. E., Hughes, M. C., Houde, V. P., Day, E. A., Marcinko, K., Crane, J. D., Mottillo, E. P., et al. (2016) · Diabetes · doi:10.2337/db16-0564 · Cited by 79
“NAFLD is associated with increased rates of hepatic DNL (43,44), and this report is the first to show that DNL can be suppressed in vivo with an acute, therapeutically relevant dose of salsalate.”
BackgroundObesity as the common soil of non‐alcoholic fatty liver disease and diabetes: Role of adipokines
Hui, E., Xu, A., Yang, H. B., & Lam, K. S. L. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12093 · Cited by 88
Hashemi, M. M., Bojd, H. H., Eskandari‐Nasab, E., Bahari, A., Hashemzehi, N.-A., Shafieipour, S., Narouie, B., Taheri, M., & Ghavami, S. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9527 · Cited by 81
“The loss of this “metabolic flexibility” would be an early sign of adipocyte dysfunction and would result in excessive postprandial lipemia, enhanced FFA, and lipid uptake by the liver and adipose tissue, (56, 57) ultimately leading to NAFLD, visceral obesity, and lower fasting adiponectin levels.”
BackgroundBallestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
“and other features of the metabolic syndrome (MetS) [10].”
BackgroundHepatic HuR modulates lipid homeostasis in response to high-fat diet
Zhang, Z., Zong, C., Jiang, M., Hu, H., Cheng, X., Ni, J., Yi, X., Jiang, B., Tian, F., Chang, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16918-x · Cited by 80
Rojas-Rodriguez, R., Ziegler, R., DeSouza, T., Majid, S., Madore, A. S., Amir, N. S., Pace, V. A., Nachreiner, D., Alfego, D., Mathew, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4145 · Cited by 79
The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
Werge, M. P., McCann, A., Galsgaard, E. D., Holst, D., Bugge, A. K., Albrechtsen, N. J. W., & Gluud, L. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051081 · Cited by 88
“The primary characteristic of NAFLD is the hepatic accumulation of lipids, mainly triacylglycerols (TAGs), due to the increased influx of free fatty acids (FFA) [2].”
BackgroundInfluentialWesterbacka, J., Kotronen, A., Fielding, B. A., Wahren, J., Hodson, L., Perttilä, J., Seppänen‐Laakso, T., Suortti, T., Arola, J. T., Hultcrantz, R. W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.064 · Cited by 84
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 72
“REVIEW ARTICLE published: 22 January 2013 doi: 10.3389/fgene.2013.00002 Molecular interactions between NAFLD and xenobiotic metabolism”
BackgroundInfluentialVidela, L. A., & Pettinelli, P. (2012) · PPAR Research · doi:10.1155/2012/107434 · Cited by 89
“In this respect, the sources that contribute to fatty liver are (i) delivery of dietary fat to the liver (contribution to liver fat ∼5%); (ii) delivery of extrahepatic nonesterified fatty acids (NEFAs) to the liver (contribution to liver fat ∼60%); (iii) the remainder of liver fat accumulation is related to hepatic de…”
BackgroundYu, D., Shu, X., Xiang, Y., Li, H., Yang, G., Gao, Y., Zheng, W., & Zhang, X. (2014) · Journal of Nutrition · doi:10.3945/jn.114.197533 · Cited by 84
“It is possible that obesity-related metabolic disorders, such as elevated adipose tissue lipolysis and insulin resistance, significantly increase the abundance of hepatic lipids, which cannot be offset by lipid oxidation and secretion enhanced by choline (41).”
BackgroundBlack, P. N., Ahowesso, C., Montefusco, D. J., Saini, N., & Dirusso, C. (2016) · MedChemComm · doi:10.1039/c6md00043f · Cited by 80
Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD
Worm, N. (2020) · Nutrients · doi:10.3390/nu12051316 · Cited by 85
Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 144
Ayonrinde, O. T. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100261 · Cited by 75
“6)(10,12,18,21) has similarities to contemporary observations of NAFLD resulting from de novo lipogenesis and lipid influx from the circulation.(79) Fig.”
BackgroundDiabetes of the Liver: The Link Between Nonalcoholic Fatty Liver Disease and HFCS‐55
Collison, K. S., Saleh, S. M., Bakheet, R. H., Al‐Rabiah, R. K., Inglis, A. L., Makhoul, N. J., Maqbool, Z. M., Zaidi, M. Z., Al‐Johi, M. A., & Al‐Mohanna, F. A. (2009) · Obesity · doi:10.1038/oby.2009.58 · Cited by 80
“Interestingly, the four- to fivefold higher level of de novo lipogenesis observed in patients with NAFLD can occur in part via increased incorporation of simple sugars and amino acids into TG (47).”
BackgroundStraznicky, N. E., Lambert, E. A., Grima, M. T., Eikelis, N., Nestel, P. J., Dawood, T., Schlaich, M. P., Masuo, K., Chopra, R., Sari, C. I., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01497.x · Cited by 75
“Current therapeutic guidelines for the MetS and NAFLD advocate weight loss (WL) and exercise as first-line treatments [15,16].”
MethodInfluentialBuqué, X., Martínez, M. J., Cano, A., Miquilena-Colina, M. E., García‐Monzón, C., Aspichueta, P., & Ochoa, B. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001966 · Cited by 86
Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients?
Finelli, C., & Tarantino, G. (2012) · PubMed · Cited by 80
Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 84
“FFAs from adipose tissue contribute to∼60% of hepatic lipid accumulation together with FFA “spillover” (11).”
BackgroundPolysaccharides influence human health via microbiota-dependent and -independent pathways
Gan, L., Wang, J., & Guo, Y. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1030063 · Cited by 81
“Moreover, approximately 40% of the lipids derive from DNL and dietary sugars and fats, whereas the remaining 60% arise from lipolysis of dysfunctional adipose tissues (114, 115).”
BackgroundSkeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 84
“[111] Furthermore, in vitro work has suggested that localized lipolysis of IMAT may flood adjacent myocytes with diacylglycerol, which then has a knock-on effect on insulin signaling.”
Postprandial Lipemia Associates with Liver Fat Content
Matikainen, N., Mänttäri, S., Westerbacka, J., Vehkavaara, S., Lundbom, N., Yki-Järvinen, H., & Taskinen, M.-R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0187 · Cited by 76
Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis
Flamment, M., Kammoun, H. L., Hainault, I., Ferré, P., & Foufelle, F. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283395e5c · Cited by 83
Chabowski, A., Żendzian‐Piotrowska, M., Konstantynowicz-Nowicka, K., Pankiewicz, W., Mikłosz, A., Łukaszuk, B., & Górski, J. (2012) · Acta Physiologica · doi:10.1111/apha.12022 · Cited by 82
“There are, although scarce, data showing that enhanced serum fatty acids availability induces lipid accumulation in liver (Wierzbicki et al. 2009) followed by the development of hepatic insulin resistance (Donnelly et al. 2005, Bradbury 2006).”
BackgroundJin, R., Le, N., Liu, S., Epperson, M., Ziegler, T. R., Welsh, J. A., Jones, D. P., McClain, C. J., & Vos, M. B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1370 · Cited by 77
Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms
Ferrandino, G., Kaspari, R. R., Spadaro, O., Reyna-Neyra, A., Perry, R. J., Cardone, R., Kibbey, R. G., Shulman, G. I., Dixit, V. D., & Carrasco, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707797114 · Cited by 77
“In NAFLD patients, DNL accounts for only ∼26% of liver TGs; the main source (∼60%) of substrates for liver TG biosynthesis is FAs generated by adipose tissue lipolysis (28).”
BackgroundGerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 84
Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes
Scapaticci, S., D’Adamo, E., Mohn, A., Chiarelli, F., & Giannini, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.639548 · Cited by 85
“The loss of action of insulin in the adipose tissue could be the root cause because of the increased release of fatty acids (FFAs) into blood stream consequent to lipolysis.”
BackgroundInfluentialFatty acid synthesis suppresses dietary polyunsaturated fatty acid use
Worthmann, A., Ridder, J., Piel, S., Evangelakos, I., Musfeldt, M., Voß, H., O’Farrell, M., Fischer, A. W., Adak, S., Sundd, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44364-y · Cited by 79
Hepatic fatty acid partitioning
Hodson, L., & Frayn, K. N. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283462e16 · Cited by 75
Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
Pettinelli, P., Obregón, A. M., & Videla, L. A. (2011) · PubMed · doi:10.1590/s0212-16112011000300003 · Cited by 85
Tainaka, T., Shimada, Y., Kuroyanagi, J., Zang, L., Oka, T., Nishimura, Y., Nishimura, N., & Tanaka, T. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-88 · Cited by 81
“in the liver, and plays a considerable role in the pathogenesis of nonalcoholic fatty liver disease [34,35].”
BackgroundRoles of Chronic Low-Grade Inflammation in the Development of Ectopic Fat Deposition
Liu, L., Mei, M., Yang, S., & Li, Q. (2014) · Mediators of Inflammation · doi:10.1155/2014/418185 · Cited by 71
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 74
Fujii, J., Homma, T., Kobayashi, S., & Seo, H. G. (2018) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v9.i1.1 · Cited by 79
A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?
van Welzen, B. J., Mudrikova, T., Idrissi, A. E., Hoepelman, A. I. M., & Arends, J. E. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0229-7 · Cited by 82
A complex role of activin A in non-alcoholic fatty liver disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Bjøro, K., Gladhaug, I. P., Berge, C., Damås, J. K., Haaland, T., Løberg, E. M., Linnestad, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.318 · Cited by 75
“Intra-hepatic accumulation of triglycerides, at least partly involving enhanced de novo FA synthesis in the liver (”
BackgroundNon-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Scorletti, E., Calder, P. C., & Byrne, C. D. (2011) · Endocrine · doi:10.1007/s12020-011-9530-x · Cited by 80
Hénin, G., Loumaye, A., Leclercq, I. A., & Lanthier, N. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100963 · Cited by 86
“64 It is therefore logical to assume that FFAs from the adipose tissue also contribute to myosteatosis.”
BackgroundLead-induced phospholipidosis and cholesterogenesis in rat tissues
Ademuyiwa, O., Agarwal, R., Chandra, R., & Behari, J. R. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.057 · Cited by 75
Schleicher, J., Tokarski, C., Marbach, E., Matz‐Soja, M., Zellmer, S., Gebhardt, R., & Schuster, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.02.004 · Cited by 86
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Yoon, H., & Soo, B. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i11.800 · Cited by 83
Gunn, P. J., Green, C. J., Pramfalk, C., & Hodson, L. (2017) · Physiological Reports · doi:10.14814/phy2.13532 · Cited by 73
“When cultured in FBS, the amount of DNL in both Huh7 and HepG2 cells could be considered supraphysiological; however, when cultured in HS DNL accounted for 18–25% in both cell lines, which is comparable to that reported for subjects with NAFLD (Donnelly et al. 2005; Lambert et al. 2014).”
ResultHo, C., Gao, Y., Zheng, D., Liu, Y., Shan, S., Fang, B., Zhao, Y., Song, D., Zhang, Y., & Li, Q. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14380 · Cited by 79
Murakami, S., Ono, A., Kawasaki, A., Takenaga, T., & Ito, T. (2018) · Amino Acids · doi:10.1007/s00726-018-2605-8 · Cited by 79
The role of adipose tissue dysfunction in hepatic insulin resistance and T2D
Sancar, G., & Birkenfeld, A. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0115 · Cited by 79
Cao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
“In the liver, dysfunctional HDL and atherogenic lipoproteins accelerate lipid accumulation and atherosclerosis—major deter-Int minants of NASH-related mortality [68].”
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.